JP2017504568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504568A5 JP2017504568A5 JP2016533105A JP2016533105A JP2017504568A5 JP 2017504568 A5 JP2017504568 A5 JP 2017504568A5 JP 2016533105 A JP2016533105 A JP 2016533105A JP 2016533105 A JP2016533105 A JP 2016533105A JP 2017504568 A5 JP2017504568 A5 JP 2017504568A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- cell
- enucleated erythroid
- pharmaceutical composition
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 117
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 117
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 117
- 238000000034 method Methods 0.000 claims description 84
- 239000008194 pharmaceutical composition Substances 0.000 claims description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 5
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 102000006306 Antigen Receptors Human genes 0.000 claims description 2
- 108010083359 Antigen Receptors Proteins 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000000989 Complement System Proteins Human genes 0.000 claims description 2
- 108010069112 Complement System Proteins Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 108090000856 Lyases Proteins 0.000 claims description 2
- 102000004317 Lyases Human genes 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000000688 bacterial toxin Substances 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 claims description 2
- 210000003040 circulating cell Anatomy 0.000 claims description 2
- 102000006834 complement receptors Human genes 0.000 claims description 2
- 108010047295 complement receptors Proteins 0.000 claims description 2
- 210000004969 inflammatory cell Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002636 mycotoxin Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 210000000267 erythroid cell Anatomy 0.000 claims 18
- 210000003013 erythroid precursor cell Anatomy 0.000 claims 4
- QKHXKQJMUZVCJM-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;azane Chemical compound N.OC(=O)[C@@H](N)CC1=CC=CC=C1 QKHXKQJMUZVCJM-QRPNPIFTSA-N 0.000 claims 2
- 102000015790 Asparaginase Human genes 0.000 claims 2
- 108010024976 Asparaginase Proteins 0.000 claims 2
- 108010073644 Cystathionine beta-synthase Proteins 0.000 claims 2
- 102100034976 Cystathionine beta-synthase Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 2
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims 2
- 108010092464 Urate Oxidase Proteins 0.000 claims 2
- 229960003272 asparaginase Drugs 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 210000001995 reticulocyte Anatomy 0.000 claims 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 1
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 description 14
- 239000013543 active substance Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 4
- 102100022002 CD59 glycoprotein Human genes 0.000 description 4
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 4
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000003124 biologic agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101710184994 Complement control protein Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000004050 Phospholipase A2 Receptors Human genes 0.000 description 2
- 108010043045 Phospholipase A2 Receptors Proteins 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- -1 sphingomyelin Chemical compound 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361962867P | 2013-11-18 | 2013-11-18 | |
| US61/962,867 | 2013-11-18 | ||
| US201361919432P | 2013-12-20 | 2013-12-20 | |
| US61/919,432 | 2013-12-20 | ||
| US201461973764P | 2014-04-01 | 2014-04-01 | |
| US61/973,764 | 2014-04-01 | ||
| US201461991319P | 2014-05-09 | 2014-05-09 | |
| US61/991,319 | 2014-05-09 | ||
| US201462006829P | 2014-06-02 | 2014-06-02 | |
| US201462006832P | 2014-06-02 | 2014-06-02 | |
| US201462006825P | 2014-06-02 | 2014-06-02 | |
| US62/006,829 | 2014-06-02 | ||
| US62/006,825 | 2014-06-02 | ||
| US62/006,832 | 2014-06-02 | ||
| US201462025367P | 2014-07-16 | 2014-07-16 | |
| US62/025,367 | 2014-07-16 | ||
| US201462059100P | 2014-10-02 | 2014-10-02 | |
| US62/059,100 | 2014-10-02 | ||
| PCT/US2014/065304 WO2015073587A2 (en) | 2013-11-18 | 2014-11-12 | Synthetic membrane-receiver complexes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087057A Division JP7116705B2 (ja) | 2013-11-18 | 2019-04-30 | 合成膜－レシーバー複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504568A JP2017504568A (ja) | 2017-02-09 |
| JP2017504568A5 true JP2017504568A5 (cg-RX-API-DMAC7.html) | 2018-05-31 |
| JP6702866B2 JP6702866B2 (ja) | 2020-06-03 |
Family
ID=52293163
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533105A Expired - Fee Related JP6702866B2 (ja) | 2013-11-18 | 2014-11-12 | 合成膜−レシーバー複合体 |
| JP2019087057A Active JP7116705B2 (ja) | 2013-11-18 | 2019-04-30 | 合成膜－レシーバー複合体 |
| JP2021095131A Pending JP2021130721A (ja) | 2013-11-18 | 2021-06-07 | 合成膜−レシーバー複合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087057A Active JP7116705B2 (ja) | 2013-11-18 | 2019-04-30 | 合成膜－レシーバー複合体 |
| JP2021095131A Pending JP2021130721A (ja) | 2013-11-18 | 2021-06-07 | 合成膜−レシーバー複合体 |
Country Status (8)
| Country | Link |
|---|---|
| US (20) | US20150182588A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3071515A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6702866B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014348683B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016011195A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2930665A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL245671B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015073587A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| AU2014348683B2 (en) | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| MX2020000621A (es) | 2014-04-01 | 2020-11-12 | Rubius Therapeutics Inc | Composiciones para usarse en inmunomodulacion. |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US10851343B2 (en) | 2015-10-14 | 2020-12-01 | Megakaryon Corporation | Method for producing purified platelets |
| BR112018008673A2 (pt) * | 2015-10-30 | 2018-11-27 | Genentech, Inc. | métodos para medir a atividade do fator d e para determinar a potência de um inibidor do fator d, método de triagem para um inibidor do fator d e kits |
| WO2017083599A1 (en) * | 2015-11-12 | 2017-05-18 | Goetzl Edward J | Platelet biomarkers and diagnostic methods for vascular diseases |
| WO2017112784A1 (en) * | 2015-12-22 | 2017-06-29 | The Trustees Of The University Of Pennsylvania | Spycatcher and spytag: universal immune receptors for t cells |
| TR201909510T4 (tr) * | 2015-12-24 | 2019-07-22 | Koninklijke Philips Nv | Hücre süspansiyonlarının saptamalarına yönelik bir yöntem ve bir sistem. |
| MX2018008515A (es) * | 2016-01-11 | 2019-05-09 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias. |
| WO2017155894A1 (en) | 2016-03-07 | 2017-09-14 | Cfgenome, Llc | Noninvasive molecular controls |
| WO2017156310A1 (en) * | 2016-03-09 | 2017-09-14 | Molecular Stethoscope, Inc. | Methods and systems for detecting tissue conditions |
| US11083702B2 (en) | 2016-04-19 | 2021-08-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism |
| WO2017190056A1 (en) * | 2016-04-28 | 2017-11-02 | William Marsh Rice University | Conversion of 1-carbon compounds to products |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US10792411B2 (en) | 2016-05-09 | 2020-10-06 | Jae-Hyung Robert CHANG | Accelerated method for preparing platelet rich plasma |
| WO2018009838A1 (en) | 2016-07-07 | 2018-01-11 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| CN110494543A (zh) | 2016-10-19 | 2019-11-22 | 弗洛设计声能学公司 | 通过声学的亲和细胞提取 |
| US10425485B2 (en) * | 2016-11-21 | 2019-09-24 | Cisco Technology, Inc. | Integrating information centric networking (ICN) over low power and lossy networks (LLNs) |
| EP3548050A1 (en) | 2016-12-02 | 2019-10-09 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| WO2018148633A1 (en) | 2017-02-13 | 2018-08-16 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| JP7179743B2 (ja) * | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| WO2018151829A1 (en) * | 2017-02-17 | 2018-08-23 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| WO2019017937A1 (en) | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASE |
| WO2019017940A1 (en) | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASE |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| KR20250056192A (ko) * | 2017-08-07 | 2025-04-25 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
| US20210369858A1 (en) * | 2017-08-16 | 2021-12-02 | Board Of Regents, The University Of Texas System | Use of exosomes for targeted delivery of therapeutic agents |
| EP4328314A3 (en) | 2017-08-22 | 2024-03-20 | Tessera Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| WO2019042628A1 (en) | 2017-08-31 | 2019-03-07 | Erytech Pharma | ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY |
| EP3449935A1 (en) | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| CN109580990B (zh) * | 2017-09-28 | 2021-08-06 | 中国医学科学院基础医学研究所 | 一种采用原子力显微镜检测细胞表面孔洞的方法 |
| WO2019084531A1 (en) | 2017-10-27 | 2019-05-02 | The Children's Hospital Of Philadelphia | MODIFIED RED GLOBES HAVING PHENOTYPES OF RARE ANTIGENS |
| US20190160102A1 (en) | 2017-11-03 | 2019-05-30 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| US20190290686A1 (en) | 2017-12-23 | 2019-09-26 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells and methods of use |
| US20190201548A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for engineering erythroid cells |
| MX2020007071A (es) | 2018-01-05 | 2020-11-11 | Platelet Biogenesis Inc | Composiciones y metodos para producir megacariocitos. |
| US20190330591A1 (en) | 2018-01-10 | 2019-10-31 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
| JP7281633B2 (ja) * | 2018-01-29 | 2023-05-26 | 地方独立行政法人東京都健康長寿医療センター | 平均赤血球年齢を決定する方法 |
| CA3092062A1 (en) | 2018-02-22 | 2019-08-29 | Entrada Therapeutics, Inc. | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy |
| RU2020132924A (ru) | 2018-03-08 | 2022-04-11 | Рубиус Терапьютикс, Инк. | Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний |
| US20190309271A1 (en) | 2018-03-20 | 2019-10-10 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating homocystinuria |
| US20190309269A1 (en) | 2018-03-20 | 2019-10-10 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating hyperuricemia and gout |
| CA3095134A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| US11987647B2 (en) | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| US11732009B2 (en) | 2018-06-08 | 2023-08-22 | Glympse Bio, Inc. | Activity sensor with tunable analyte |
| US11028425B2 (en) | 2018-06-08 | 2021-06-08 | Glympse Bio, Inc. | Diagnosis and monitoring of liver disease |
| WO2020006539A1 (en) | 2018-06-29 | 2020-01-02 | Platelet Biogenesis, Inc. | Compositions for drug delivery and methods of use thereof |
| US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US20210395704A1 (en) * | 2018-10-29 | 2021-12-23 | President And Fellows Of Harvard College | Nanobody-glycan modifying enzyme fusion proteins and uses thereof |
| WO2020113101A1 (en) * | 2018-11-30 | 2020-06-04 | Cellphire, Inc. | Platelets loaded with anti-cancer agents |
| EP3886879A4 (en) * | 2018-11-30 | 2022-12-07 | Cellphire Inc. | PLATES AS DELIVERY AGENTS |
| JP2022513705A (ja) | 2018-12-03 | 2022-02-09 | ルビウス セラピューティクス， インコーポレイテッド | Ｈｌａ－ｅおよびｈｌａ－ｇ分子を含む人工抗原提示細胞、ならびに使用の方法 |
| PH12021551398A1 (en) * | 2018-12-11 | 2022-11-07 | Q32 Bio Inc | Fusion protein constructs for complement associated disease |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
| WO2020150608A1 (en) | 2019-01-18 | 2020-07-23 | Flagship Pioneering, Inc. | Trem compositions and uses thereof |
| US20200291355A1 (en) | 2019-02-20 | 2020-09-17 | Rubius Therapeutics, Inc. | Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use |
| WO2020191416A2 (en) | 2019-02-28 | 2020-09-24 | Georgia Tech Research Corporation | Compositions and methods for logic-gated profiling of biologic activity |
| CA3128626A1 (en) | 2019-03-04 | 2020-09-10 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides and pharmaceutical compositions thereof |
| WO2020198403A2 (en) | 2019-03-25 | 2020-10-01 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising modified circular polyribonucleotides and uses thereof |
| CN114007627A (zh) | 2019-04-26 | 2022-02-01 | 鲁比厄斯治疗法股份有限公司 | 包含去核类红细胞的缓冲组合物 |
| CN114072159A (zh) | 2019-05-03 | 2022-02-18 | 塞尔菲乐有限公司 | 用于生产血液产品的材料和方法 |
| JP2022532174A (ja) | 2019-05-10 | 2022-07-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 修飾多能性細胞 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| JP2022533252A (ja) | 2019-05-24 | 2022-07-21 | ルビウス セラピューティクス， インコーポレイテッド | 脱核赤血球細胞を生成する方法 |
| EP3976782A1 (en) | 2019-05-31 | 2022-04-06 | Flagship Pioneering, Inc. | Uses of trem compositions to modulate trna pools |
| AU2020292427A1 (en) | 2019-06-14 | 2022-01-06 | Flagship Pioneering Innovations Vi, Llc | Circular RNAs for cellular therapy |
| US20220305128A1 (en) | 2019-06-19 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| PH12021553235A1 (en) | 2019-06-26 | 2022-08-22 | Univ Colorado Regents | Drug product for enzyme therapy for treatment of homocystinuria |
| CA3150936A1 (en) | 2019-08-16 | 2021-02-25 | Cellphire, Inc. | Thrombosomes as an antiplatelet agent reversal agent |
| CN110941181B (zh) * | 2019-08-29 | 2023-01-20 | 广东工业大学 | 一种压电陶瓷连接的刚柔耦合运动平台控制方法 |
| EP4025048A2 (en) | 2019-09-05 | 2022-07-13 | Hemanext Inc. | Methods for the preservation of reagent red blood cells using carbon monoxide |
| GB201913592D0 (en) * | 2019-09-20 | 2019-11-06 | Univ Bristol | Product for therapy and methods |
| CA3154076A1 (en) * | 2019-10-15 | 2021-04-22 | Tobias Deuse | Transplanted cell protection via fc sequestration |
| AU2020379762A1 (en) | 2019-11-04 | 2022-05-26 | Flagship Pioneering, Inc. | TREM compositions for con-rare codons and related uses |
| WO2021092073A1 (en) | 2019-11-04 | 2021-05-14 | Flagship Pioneering, Inc. | Methods of modifying a nucleic acid sequence |
| CA3160464A1 (en) | 2019-11-04 | 2021-05-14 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells using taurine or hypotaurine |
| CA3159917A1 (en) | 2019-11-04 | 2021-05-14 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells using myo-inositol |
| GB201918586D0 (en) | 2019-12-17 | 2020-01-29 | Patterson James | Engineered platelets for targeted delivery of a therapeutic agent |
| WO2021155171A1 (en) | 2020-01-29 | 2021-08-05 | Flagship Pioneering Innovations Vi, Llc | Delivery of compositions comprising circular polyribonucleotides |
| EP4096682A1 (en) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Compositions for translation and methods of use thereof |
| CN115279415A (zh) | 2020-01-29 | 2022-11-01 | 旗舰创业创新第六有限责任公司 | 用于蛋白调节的包含线性多核糖核苷酸的组合物及其用途 |
| WO2021158646A1 (en) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Treatment of von willebrand disease |
| US20210246426A1 (en) | 2020-02-10 | 2021-08-12 | Rubius Therapeutics, Inc. | Engineered Erythroid Cells Including HLA-G Polypeptides and Methods of Use Thereof |
| WO2021183818A1 (en) * | 2020-03-12 | 2021-09-16 | University Of Florida Research Foundation, Incorporated | Recombinant oxalate oxidase and uses thereof |
| EP4125947A4 (en) * | 2020-03-27 | 2024-06-12 | Platelet Biogenesis, Inc. | NOVEL ANUCLATED CELLS FOR THE TREATMENT OF DISEASES |
| US20230193311A1 (en) | 2020-05-20 | 2023-06-22 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| AU2021275223A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| EP4153152A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for producing human polyclonal antibodies |
| EP4158031A1 (en) | 2020-05-29 | 2023-04-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and methods relating thereto |
| CA3182026A1 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| IL299048A (en) | 2020-06-14 | 2023-02-01 | Vertex Pharma | Variants of complement factor - 1 fusion structures and preparations containing them and their uses |
| WO2021262799A1 (en) | 2020-06-23 | 2021-12-30 | Flagship Pioneering, Inc. | Anti-viral compounds and methods of using same |
| JP2023542492A (ja) | 2020-09-03 | 2023-10-10 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 免疫原性組成物及びその使用 |
| CA3194956A1 (en) | 2020-09-11 | 2022-03-17 | Glympse Bio, Inc. | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment |
| CA3206285A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| WO2022150578A1 (en) | 2021-01-08 | 2022-07-14 | Rubius Therapeutics, Inc. | Methods of treating a tumor in a human subject |
| US20220273724A1 (en) | 2021-02-17 | 2022-09-01 | Cellphire Inc. | Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy |
| TW202304482A (zh) | 2021-03-14 | 2023-02-01 | 美商盧比亞斯治療公司 | 於個體中增加nkg2d陽性淋巴球之方法及其用途 |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| TW202317179A (zh) | 2021-06-03 | 2023-05-01 | 美商盧比亞斯治療公司 | 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法 |
| WO2023009547A1 (en) | 2021-07-26 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
| IL311450A (en) | 2021-09-17 | 2024-05-01 | Flagship Pioneering Innovations Vi Llc | Compositions and methods for producing circular polyribonucleotides |
| WO2023044774A1 (en) * | 2021-09-24 | 2023-03-30 | Sichuan Clover Biopharmaceuticals, Inc. | Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file |
| WO2023069397A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| CA3239266A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Coronavirus immunogen compositions and their uses |
| MX2024006440A (es) | 2021-11-24 | 2024-08-19 | Flagship Pioneering Innovations Vi Llc | Composiciones inmunogenicas y sus usos. |
| US20250368688A1 (en) | 2021-11-24 | 2025-12-04 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| US20250051386A1 (en) | 2021-12-22 | 2025-02-13 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| CN118922211A (zh) | 2021-12-23 | 2024-11-08 | 旗舰创业创新六公司 | 编码抗融合多肽的环状多核糖核苷酸 |
| AU2023269030A1 (en) | 2022-05-09 | 2024-11-14 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| EP4522753A2 (en) | 2022-05-13 | 2025-03-19 | Flagship Pioneering Innovations VII, LLC | Double stranded dna compositions and related methods |
| KR20250019772A (ko) | 2022-05-25 | 2025-02-11 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | 종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법 |
| AU2023276715A1 (en) | 2022-05-25 | 2025-01-09 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
| CA3253432A1 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | CYTOKINE COMPOSITIONS AND MODULATION METHODS |
| EP4532765A2 (en) | 2022-05-25 | 2025-04-09 | Flagship Pioneering Innovations VII, LLC | Compositions and methods for modulation of immune responses |
| AU2023277636A1 (en) | 2022-05-25 | 2024-11-21 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
| WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| KR20250099195A (ko) | 2022-10-31 | 2025-07-01 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법 |
| CN120435298A (zh) | 2022-11-08 | 2025-08-05 | 旗舰创业创新第六有限责任公司 | 用于产生环状多核糖核苷酸的组合物和方法 |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
| IL322201A (en) | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA structures containing modified uracil |
| WO2024173836A2 (en) | 2023-02-17 | 2024-08-22 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified cytosine |
| WO2024173945A1 (en) * | 2023-02-17 | 2024-08-22 | Abbott Diabetes Care Inc. | Methods for single cell analysis of glucose internalization |
| WO2024192422A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| KR20250162610A (ko) | 2023-03-15 | 2025-11-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도 |
| WO2024216128A1 (en) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trems for use in correction of missense mutations |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025076409A1 (en) * | 2023-10-06 | 2025-04-10 | Cz Biohub Sf, Llc | Generation of antigen-specific t and b cells using engineered commensals |
| CN117025553B (zh) * | 2023-10-09 | 2023-12-19 | 深圳市梓健生物科技有限公司 | 一种在非超低温下保持病毒活力的病毒保存液及其制备方法 |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327710A (en) | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
| IL86650A0 (en) | 1987-06-30 | 1988-11-30 | Biophor Corp | Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane |
| US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US4935223A (en) | 1988-08-04 | 1990-06-19 | Board Of Regents, The University Of Texas System | Labeled cells for use in imaging |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| ES2109260T3 (es) | 1991-06-14 | 1998-01-16 | Europ Communities | Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas. |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5599705A (en) | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
| US6984379B1 (en) | 1994-04-08 | 2006-01-10 | Children's Hospital of LosAngeles | Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US5648248A (en) | 1994-12-30 | 1997-07-15 | Boehringer Ingelheim International Gmbh | Methods for producing differentiated cells from immature hematopoietic cells |
| US6060052A (en) | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
| TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| WO1998016201A1 (en) | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| IL130035A0 (en) | 1996-11-21 | 2000-02-29 | New York Blood Ct Inc | Method for conversion of blood type |
| EP0882448B1 (en) | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor |
| WO1999067360A2 (en) | 1998-06-25 | 1999-12-29 | Hemosol Inc. | Media and methods for expansion of erythroid stem cells for the production of hemoglobin |
| US6197526B1 (en) | 1999-01-04 | 2001-03-06 | Dyax Corp. | Polypeptides for binding human factor VIII and fragments of human factor VIII |
| US7109170B2 (en) | 1999-06-16 | 2006-09-19 | Saint Louis University | Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor |
| US6624289B1 (en) | 1999-06-16 | 2003-09-23 | Saint Louis University | Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor |
| JP2003503426A (ja) | 1999-07-02 | 2003-01-28 | ジェネンテック・インコーポレーテッド | ＦＶＩＩａアンタゴニスト |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| US6495351B2 (en) | 2000-02-08 | 2002-12-17 | Gendel Limited | Loading system and method for using the same |
| US20020151004A1 (en) | 2000-07-24 | 2002-10-17 | Roger Craig | Delivery vehicles and methods for using the same |
| AU2002306766A1 (en) | 2001-03-16 | 2002-10-03 | Johns Hopkins University School Of Medicine | Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules |
| US20030207247A1 (en) | 2001-12-05 | 2003-11-06 | Cerus Corporation | Preparation of red blood cells having reduced immunogenicity |
| US20030133922A1 (en) | 2002-01-15 | 2003-07-17 | Kasha John R. | Oral tolerance using allogeneic platelets in ITP |
| US7427603B2 (en) | 2002-09-26 | 2008-09-23 | The Children's Medical Center Corporation | Method of enhancing proliferation and/or hematopoietic differentiation of stem cells |
| ES2348868T3 (es) | 2002-12-13 | 2010-12-16 | Genetix Pharmaceuticals Inc. | Vectores retrovirales terapeuticos para terapia genica. |
| DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| WO2005118780A1 (en) * | 2004-06-04 | 2005-12-15 | Universite Pierre Et Marie Curie - Paris Vi | A method for producing red blood cells |
| KR20070037444A (ko) | 2004-06-15 | 2007-04-04 | 백스터 인터내셔널 인코포레이티드 | 고체 미립자성 치료제의 생체외 적용방법 |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| US7343146B2 (en) * | 2004-08-13 | 2008-03-11 | Nokia Corporation | Single chip LNA and VCO having similar resonant circuit topology and using same calibration signal to compensate for process variations |
| DE102004054536A1 (de) * | 2004-11-06 | 2006-05-11 | Capsulution Nanoscience Ag | Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel |
| FR2884717B1 (fr) | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
| PT1926813T (pt) | 2005-09-23 | 2016-09-06 | Consejo Superior Investigacion | Populações de células que têm atividade imunorreguladora, método para isolamento e usos |
| FR2891843A1 (fr) | 2005-10-06 | 2007-04-13 | Erytech Pharma Soc Par Actions | Erythrocytes contenant du 5-fluorouracile |
| US7462485B2 (en) * | 2005-10-07 | 2008-12-09 | Glaser Lawrence F | Modified erythrocytes and uses thereof |
| US20070243137A1 (en) | 2006-04-18 | 2007-10-18 | Nanoprobes, Inc. | Cell and sub-cell methods for imaging and therapy |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| FR2925339B1 (fr) | 2007-12-24 | 2010-03-05 | Erytech Pharma | Medicament pour le traitement du cancer du pancreas |
| EP2242507B1 (en) | 2008-02-13 | 2013-02-20 | Erytech Pharma | Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease |
| FR2928270B1 (fr) | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| US8231895B2 (en) | 2008-05-22 | 2012-07-31 | Universidade De Coimbra | Targeted delivery to human diseases and disorders |
| US8211656B2 (en) | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
| FR2938332B1 (fr) | 2008-11-07 | 2011-11-25 | Erytech Pharma | Test predictif de la neutralisation de l'activite asparaginase |
| JP2012512175A (ja) * | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| FR2944106B1 (fr) | 2009-04-03 | 2012-09-28 | Erytech Pharma | Methode de dosage de l'inositol hexaphosphate (ihp). |
| WO2010117464A1 (en) | 2009-04-09 | 2010-10-14 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
| WO2010133298A1 (en) | 2009-05-19 | 2010-11-25 | Eth Zurich | Control of uric acid homeostasis |
| CA2778669C (en) | 2009-10-27 | 2019-04-16 | Erytech Pharma | Composition to induce specific immune tolerance |
| EP2544533A4 (en) | 2010-03-12 | 2014-07-09 | Univ California | PERIODIC LOAD RELEASE FROM NANOPARTICLE STABILIZED LIPOSOMES |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| ES2764105T3 (es) | 2011-10-17 | 2020-06-02 | Massachusetts Inst Technology | Administración intracelular |
| EP2814500B1 (en) | 2012-02-15 | 2020-01-08 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Erythrocyte-binding therapeutics |
| AU2013203832B2 (en) * | 2012-03-13 | 2016-09-15 | Celularity Inc. | Modified erythrocyte precursor cells and uses thereof |
| CN104394884A (zh) * | 2012-03-21 | 2015-03-04 | 爱瑞泰克药物公司 | 用于治疗急性髓细胞白血病(aml)的药剂 |
| US8975072B2 (en) | 2012-07-20 | 2015-03-10 | Riken | Human erythroid progenitor cell line comprising HPV E6/E7 operably linked to an inducible promoter and method for producing human enucleated red blood cells |
| US20150246085A1 (en) | 2012-11-01 | 2015-09-03 | The Sydney Children's Hospital Network (Randwick & Westmead) | Genetically-Modified Probiotic for Treatment of Phenylketonuria |
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| CN103224957B (zh) * | 2013-04-16 | 2017-08-04 | 福建三一造血技术有限公司 | 体外诱导生成含L‑ASPase II的红细胞药物的方法 |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| US10471099B2 (en) | 2013-05-10 | 2019-11-12 | Whitehead Institute For Biomedical Research | In vitro production of red blood cells with proteins comprising sortase recognition motifs |
| BR112015028278B1 (pt) | 2013-05-10 | 2022-12-20 | Erydel S.P.A | Processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico, eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico, composição farmacêutica e uso terapêutico dos ditos eritrócitos |
| AU2014262469B2 (en) | 2013-05-10 | 2019-11-14 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| EP2813234A1 (en) | 2013-06-11 | 2014-12-17 | Erytech Pharma | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof |
| AU2014348683B2 (en) | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| MX2020000621A (es) | 2014-04-01 | 2020-11-12 | Rubius Therapeutics Inc | Composiciones para usarse en inmunomodulacion. |
| WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| EP3187190A1 (en) | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| MX2018008515A (es) | 2016-01-11 | 2019-05-09 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias. |
| WO2018009838A1 (en) | 2016-07-07 | 2018-01-11 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
| EP3548050A1 (en) | 2016-12-02 | 2019-10-09 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| WO2018151829A1 (en) | 2017-02-17 | 2018-08-23 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| EP4328314A3 (en) | 2017-08-22 | 2024-03-20 | Tessera Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| US20190160102A1 (en) | 2017-11-03 | 2019-05-30 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| US20190201548A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for engineering erythroid cells |
-
2014
- 2014-11-12 AU AU2014348683A patent/AU2014348683B2/en not_active Ceased
- 2014-11-12 CA CA2930665A patent/CA2930665A1/en not_active Abandoned
- 2014-11-12 JP JP2016533105A patent/JP6702866B2/ja not_active Expired - Fee Related
- 2014-11-12 BR BR112016011195A patent/BR112016011195A2/pt not_active IP Right Cessation
- 2014-11-12 WO PCT/US2014/065304 patent/WO2015073587A2/en not_active Ceased
- 2014-11-12 EP EP14824599.6A patent/EP3071515A2/en not_active Withdrawn
- 2014-12-23 US US14/581,486 patent/US20150182588A1/en not_active Abandoned
-
2015
- 2015-06-12 US US14/738,414 patent/US9644180B2/en not_active Expired - Fee Related
-
2016
- 2016-05-17 US US15/157,006 patent/US20160257932A1/en not_active Abandoned
- 2016-05-17 IL IL245671A patent/IL245671B/en active IP Right Grant
-
2017
- 2017-03-29 US US15/473,421 patent/US10344263B2/en active Active
- 2017-10-13 US US15/783,921 patent/US10329531B2/en active Active
- 2017-11-28 US US15/824,877 patent/US10253296B2/en active Active
-
2018
- 2018-02-20 US US15/900,029 patent/US20180187154A1/en not_active Abandoned
- 2018-02-20 US US15/899,895 patent/US20180187153A1/en not_active Abandoned
- 2018-03-19 US US15/925,212 patent/US10301593B2/en active Active
- 2018-03-29 US US15/940,215 patent/US20180216067A1/en not_active Abandoned
- 2018-03-29 US US15/940,069 patent/US20180265847A1/en not_active Abandoned
- 2018-11-19 US US16/195,811 patent/US10301594B1/en active Active
-
2019
- 2019-04-30 JP JP2019087057A patent/JP7116705B2/ja active Active
- 2019-05-10 US US16/409,573 patent/US20190264177A1/en not_active Abandoned
- 2019-05-10 US US16/409,576 patent/US10557119B2/en not_active Expired - Fee Related
- 2019-05-30 US US16/426,905 patent/US20190316091A1/en not_active Abandoned
- 2019-05-30 US US16/426,880 patent/US20190316090A1/en not_active Abandoned
- 2019-06-04 US US16/431,236 patent/US20190309261A1/en not_active Abandoned
- 2019-06-04 US US16/431,270 patent/US20190309262A1/en not_active Abandoned
- 2019-08-23 US US16/549,840 patent/US20190376034A1/en not_active Abandoned
- 2019-09-16 US US16/572,129 patent/US20200002674A1/en not_active Abandoned
-
2020
- 2020-10-28 AU AU2020260424A patent/AU2020260424A1/en not_active Abandoned
-
2021
- 2021-03-21 IL IL281666A patent/IL281666A/en unknown
- 2021-06-07 JP JP2021095131A patent/JP2021130721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504568A5 (cg-RX-API-DMAC7.html) | ||
| Safdar et al. | Exosomes as mediators of the systemic adaptations to endurance exercise | |
| Sun et al. | The phenotype and functional alterations of macrophages in mice with hyperglycemia for long term | |
| Kharraz et al. | Understanding the process of fibrosis in Duchenne muscular dystrophy | |
| Walley et al. | The central role of proprotein convertase subtilisin/kexin type 9 in septic pathogen lipid transport and clearance | |
| US20210290538A1 (en) | Milk vesicles for use in delivering biological agents | |
| Dumas et al. | Raising the ‘good’oxidants for immune protection | |
| JP2016040335A5 (cg-RX-API-DMAC7.html) | ||
| CN106661094B (zh) | 骨形态发生蛋白的治疗用途 | |
| JP2013530988A5 (cg-RX-API-DMAC7.html) | ||
| Ho et al. | Tunable surface charge enables the electrostatic adsorption-controlled release of neuroprotective peptides from a hydrogel–nanoparticle drug delivery system | |
| CA2918196A1 (en) | Methods and compositions of treating autoimmune diseases | |
| JP2015520188A5 (cg-RX-API-DMAC7.html) | ||
| Cremel et al. | Innovative approach in Pompe disease therapy: induction of immune tolerance by antigen-encapsulated red blood cells | |
| US20160213759A1 (en) | Therapeutic asparaginases | |
| JP6815413B2 (ja) | 肝組織損傷及びその関連疾患を予防及び治療するための方法 | |
| Kulakova et al. | The contribution of macrophage plasticity to inflammatory arthritis and their potential as therapeutic targets | |
| WO2019213686A1 (en) | Therapeutic compositions and uses therefor | |
| An et al. | Extracellular vesicles in Sepsis: pathogenic roles, organ damage, and therapeutic implications | |
| Wu et al. | Brain Delivery Strategies for Biomacromolecular Drugs: Intranasal Administration | |
| CN104168910B (zh) | 肽及其用途 | |
| CN113438945A (zh) | 膜联蛋白涂覆的颗粒 | |
| AU2013246870B2 (en) | Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis | |
| WO2024150064A9 (en) | Lipid binding protein molecule therapy | |
| US9839671B2 (en) | Peptide and uses therefor |